SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: eico20 who wrote (1478)9/1/2015 12:43:40 PM
From: Mirror Image   of 2026
 
launches have not done anything in the past so no surprise, market getting hammered though, I think the real news is the Rayva results this month, if something happened with femprox that would be significant too


Eico - If they partner Femprox and Apricus receives a decent upfront payment in addition to certain Clinical, Regulatory and Sales Milestones ( and possibly royalties ). I expect the share price to go vertical. Femprox was basically written off by the market.

RayVa - The language utilized by the company signals that they will go through with a Phase 2B clinical trial.
That would mean that the Phase 2A was successful. We must also remember that there is no alternative to address this condition. So what could we compare the results against? I am curious as to what the results will bring us.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News